Shots:
- Lupin & SteinCares have entered into a license & supply agreement to commercialize Lupin’s ranibizumab biosimilar in Latin America excl. Mexico & Argentina
- As per the deal, SteinCares will be responsible for the biosimilar’s regulatory filings, registration, & commercialization in LATAM licensed states, while Lupin will oversee its manufacturing
- Ranibizumab is a recombinant humanized IgG1 mAb fragment that targets & inhibits VEGF-A for the treatment of wet age-related macular degeneration, retinal vein occlusion-related macular edema, diabetic macular edema, diabetic retinopathy, & myopic choroidal neovascularization
Ref: Lupin | Image: Lupin & SteinCares| Press Release
Related News:- Sandoz Launches Pyzchiva Autoinjector (Biosimilar, Stelara) in the EU for Chronic Inflammatory Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
